LRMR

SEC source: 0001062993-24-011568 · form4.xml · nonDerivative · entry 1

Hamilton Thomas Edward · CIK 0001769848 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 564,798

F1 · shares: Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. (the "Company") at the offering price, which closed on February 16, 2024.

SEC source: 0001062993-24-003312 · form4.xml · nonDerivative · entry 1

THOMAS FRANK E · CIK 0001242616 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

SEC source: 0001062993-24-001085 · form4.xml · derivative · entry 2

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2034-01-17

F2 · derivative.exercise_date: The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0001062993-24-001085 · form4.xml · nonDerivative · entry 1

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,996

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

SEC source: 0001062993-24-001086 · form4.xml · derivative · entry 2

Shankar Gopi · CIK 0001965014 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2034-01-17

F2 · derivative.exercise_date: The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0001062993-24-001086 · form4.xml · nonDerivative · entry 1

Shankar Gopi · CIK 0001965014 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,500

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

SEC source: 0001062993-24-001084 · form4.xml · derivative · entry 2

Clayton Russell · CIK 0001530072 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2034-01-17

F2 · derivative.exercise_date: The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0001062993-24-001084 · form4.xml · nonDerivative · entry 1

Clayton Russell · CIK 0001530072 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

SEC source: 0001062993-24-001083 · form4.xml · derivative · entry 2

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 396,750

Underlying: Common Stock · 396,750 shares

Expires 2034-01-17

F2 · derivative.exercise_date: The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0001062993-24-001083 · form4.xml · nonDerivative · entry 1

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 332,954

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

SEC source: 0001062993-23-022200 · form4.xml · nonDerivative · entry 1

Shankar Gopi · CIK 0001965014 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.768, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

SEC source: 0001062993-23-019067 · form4.xml · derivative · entry 1

SHERMAN JEFFREY W · CIK 0001230482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,600

Underlying: Common Stock · 16,600 shares

Expires 2033-10-03

F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months commencing on November 3, 2023, subject to the Reporting Person's continued service on the Board of Directors of the Company through each applicable vesting date.

SEC source: 0001062993-23-014993 · form4.xml · derivative · entry 1

Clayton Russell · CIK 0001530072 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2033-07-17

F1 · derivative.exercise_date: The option vests 25% on July 17, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0001062993-23-011545 · form4.xml · nonDerivative · entry 1

Truitt Joseph · CIK 0001452429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,750

SEC source: 0001062993-23-011547 · form4.xml · nonDerivative · entry 1

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,746

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.71 to $3.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

SEC source: 0001062993-23-011546 · form4.xml · nonDerivative · entry 1

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 266,829

SEC source: 0001193805-23-000711 · e618621_4-larimar.xml · derivative · entry 1

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Through Deerfield Management Company, L.P.

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2033-05-09

F1 · shares: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F2 · derivative.exercise_date: The option was granted on May 9, 2023 and is scheduled to vest on the earlier of May 9, 2024 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer.

F1 · derivative.underlying_shares: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F1 · balance_after: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F1 · ownership.nature: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F3 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001062993-23-010808 · form4.xml · derivative · entry 1

Truitt Joseph · CIK 0001452429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2033-05-09

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0001062993-23-010805 · form4.xml · derivative · entry 1

THOMAS FRANK E · CIK 0001242616 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2033-05-09

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0001062993-23-010806 · form4.xml · derivative · entry 1

LEFF JONATHAN S · CIK 0001215242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2033-05-09

F1 · shares: The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.

F2 · derivative.exercise_date: The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

F1 · derivative.underlying_shares: The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.

F1 · balance_after: The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.

SEC source: 0001062993-23-010807 · form4.xml · derivative · entry 1

Hamilton Thomas Edward · CIK 0001769848 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2033-05-09

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0000899243-23-004438 · doc4.xml · derivative · entry 1

Shankar Gopi · CIK 0001965014 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2033-02-07

F1 · derivative.exercise_date: The option vests 25% on February 7, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0000899243-23-003735 · doc4.xml · derivative · entry 2

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2033-01-31

F2 · derivative.exercise_date: The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0000899243-23-003735 · doc4.xml · nonDerivative · entry 1

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,746

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

SEC source: 0000899243-23-003734 · doc4.xml · derivative · entry 2

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,000

Underlying: Common Stock · 325,000 shares

Expires 2033-01-31

F2 · derivative.exercise_date: The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0000899243-23-003734 · doc4.xml · nonDerivative · entry 1

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,829

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

SEC source: 0001062993-22-019646 · form4.xml · nonDerivative · entry 1

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,746

F1 · shares: Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022.

SEC source: 0001062993-22-019645 · form4.xml · nonDerivative · entry 1

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,829

F1 · shares: Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022.

SEC source: 0001193805-22-001296 · e621937_4-larimar.xml · nonDerivative · entry 4

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt III, L.P. · CIK 0001610540 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt HIF, L.P. · CIK 0001665736 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt IV, L.P. · CIK 0001713467 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · Director · 10% owner · * Director by Deputization

Deerfield Healthcare Innovations Fund, L.P. · CIK 0001646981 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Partners, L.P.

Disclosed balance after: 2,777,777

F1 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F2 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001193805-22-001296 · e621937_4-larimar.xml · nonDerivative · entry 3

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt III, L.P. · CIK 0001610540 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt HIF, L.P. · CIK 0001665736 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt IV, L.P. · CIK 0001713467 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · Director · 10% owner · * Director by Deputization

Deerfield Healthcare Innovations Fund, L.P. · CIK 0001646981 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Healthcare Innovations Fund, L.P.

Disclosed balance after: 4,721,197

F1 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F2 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001193805-22-001296 · e621937_4-larimar.xml · nonDerivative · entry 2

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt III, L.P. · CIK 0001610540 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt HIF, L.P. · CIK 0001665736 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt IV, L.P. · CIK 0001713467 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · Director · 10% owner · * Director by Deputization

Deerfield Healthcare Innovations Fund, L.P. · CIK 0001646981 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Private Design Fund IV, L.P.

Disclosed balance after: 4,721,200

F1 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F2 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001193805-22-001296 · e621937_4-larimar.xml · nonDerivative · entry 1

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt III, L.P. · CIK 0001610540 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt HIF, L.P. · CIK 0001665736 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt IV, L.P. · CIK 0001713467 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · Director · 10% owner · * Director by Deputization

Deerfield Healthcare Innovations Fund, L.P. · CIK 0001646981 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Private Design Fund III, L.P.

Disclosed balance after: 4,721,183

F1 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F2 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001062993-22-019753 · form4.xml · nonDerivative · entry 1

Hamilton Thomas Edward · CIK 0001769848 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,590

F1 · shares: Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022.

SEC source: 0001193805-22-000771 · e621645_4-larimar.xml · derivative · entry 1

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Management Company, L.P.

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2032-05-10

F1 · shares: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F2 · derivative.exercise_date: The option was granted on May 10, 2022 and is scheduled to vest on the earlier of May 10, 2023 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer.

F1 · derivative.underlying_shares: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F1 · balance_after: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F1 · ownership.nature: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F3 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001062993-22-012307 · form4.xml · derivative · entry 1

Truitt Joseph · CIK 0001452429 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2032-05-10

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0001062993-22-012308 · form4.xml · derivative · entry 1

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-05-10

F1 · derivative.exercise_date: The option vests 25% on May 10, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates.

SEC source: 0001062993-22-012306 · form4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2032-05-10

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0001062993-22-012303 · form4.xml · derivative · entry 1

THOMAS FRANK E · CIK 0001242616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2032-05-10

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0001062993-22-012304 · form4.xml · derivative · entry 1

LEFF JONATHAN S · CIK 0001215242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2032-05-10

F1 · shares: The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.

F2 · derivative.exercise_date: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

F1 · derivative.underlying_shares: The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.

F1 · balance_after: The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.

SEC source: 0001062993-22-012309 · form4.xml · derivative · entry 1

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-05-10

F1 · derivative.exercise_date: The option vests 25% on May 10, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates.

SEC source: 0001062993-22-012305 · form4.xml · derivative · entry 1

Hamilton Thomas Edward · CIK 0001769848 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2032-05-10

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0001062993-22-001320 · form4.xml · derivative · entry 1

Celano Michael · CIK 0001377582 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-01-18

F1 · derivative.exercise_date: The option vests 25% on January 18, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0001062993-22-001319 · form4.xml · derivative · entry 1

BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,000

Underlying: Common Stock · 182,000 shares

Expires 2032-01-18

F1 · derivative.exercise_date: The option vests 25% on January 18, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

SEC source: 0001193805-21-000974 · e620772_4-larimar.xml · nonDerivative · entry 3

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt III, L.P. · CIK 0001610540 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt HIF, L.P. · CIK 0001665736 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt IV, L.P. · CIK 0001713467 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · Director · 10% owner · * Director by Deputization

Deerfield Healthcare Innovations Fund, L.P. · CIK 0001646981 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Healthcare Innovations Fund, L.P.

Disclosed balance after: 1,943,420

F1 · balance_after: The shares reported herein as being held through Deerfield Private Design Fund III, L.P. ("Fund III"), Deerfield Private Design Fund IV, L.P. ("Fund IV") and Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF" and, collectively with Fund III and Fund IV, the "Funds") include shares that were previously reported as being held indirectly through Chondrial Therapeutics Holdings, LLC ("Chondrial"), which shares were distributed to the Funds pursuant to a pro rata distribution to the members of Chondrial.

F2 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Fund III. Deerfield Mgmt IV, L.P. is the general partner of Fund IV. Deerfield Mgmt HIF, L.P. is the general partner of Deerfield HIF. Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F3 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001193805-21-000974 · e620772_4-larimar.xml · nonDerivative · entry 2

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt III, L.P. · CIK 0001610540 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt HIF, L.P. · CIK 0001665736 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt IV, L.P. · CIK 0001713467 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · Director · 10% owner · * Director by Deputization

Deerfield Healthcare Innovations Fund, L.P. · CIK 0001646981 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Private Design Fund IV, L.P.

Disclosed balance after: 1,943,423

F1 · balance_after: The shares reported herein as being held through Deerfield Private Design Fund III, L.P. ("Fund III"), Deerfield Private Design Fund IV, L.P. ("Fund IV") and Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF" and, collectively with Fund III and Fund IV, the "Funds") include shares that were previously reported as being held indirectly through Chondrial Therapeutics Holdings, LLC ("Chondrial"), which shares were distributed to the Funds pursuant to a pro rata distribution to the members of Chondrial.

F2 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Fund III. Deerfield Mgmt IV, L.P. is the general partner of Fund IV. Deerfield Mgmt HIF, L.P. is the general partner of Deerfield HIF. Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F3 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001193805-21-000974 · e620772_4-larimar.xml · nonDerivative · entry 1

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt III, L.P. · CIK 0001610540 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt HIF, L.P. · CIK 0001665736 · Director · 10% owner · * Director by Deputization

Deerfield Mgmt IV, L.P. · CIK 0001713467 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · Director · 10% owner · * Director by Deputization

Deerfield Healthcare Innovations Fund, L.P. · CIK 0001646981 · Director · 10% owner · * Director by Deputization

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Private Design Fund III, L.P.

Disclosed balance after: 1,943,406

F1 · balance_after: The shares reported herein as being held through Deerfield Private Design Fund III, L.P. ("Fund III"), Deerfield Private Design Fund IV, L.P. ("Fund IV") and Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF" and, collectively with Fund III and Fund IV, the "Funds") include shares that were previously reported as being held indirectly through Chondrial Therapeutics Holdings, LLC ("Chondrial"), which shares were distributed to the Funds pursuant to a pro rata distribution to the members of Chondrial.

F2 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Fund III. Deerfield Mgmt IV, L.P. is the general partner of Fund IV. Deerfield Mgmt HIF, L.P. is the general partner of Deerfield HIF. Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

F3 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001192482-21-000601 · edgar.xml · nonDerivative · entry 1

Hamilton Thomas Edward · CIK 0001769848 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,130

SEC source: 0001193805-21-000685 · e620613_4-larimar.xml · derivative · entry 1

Flynn James E · CIK 0001352546 · Director · 10% owner · * Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · * Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Management Company, L.P.

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2031-05-12

F1 · shares: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F2 · derivative.exercise_date: The option was granted on May 12, 2021 and is scheduled to vest on the earlier of May 12, 2022 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service with the Issuer through each applicable vesting date.

F1 · derivative.underlying_shares: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F1 · balance_after: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F1 · ownership.nature: Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

F3 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001192482-21-000440 · edgar.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2031-05-12

F1 · derivative.exercise_date: The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

SEC source: 0001192482-21-000439 · edgar.xml · derivative · entry 1

THOMAS FRANK E · CIK 0001242616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2031-05-12

F1 · derivative.exercise_date: The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.